heart%20failure%20-%20acute
HEART FAILURE - ACUTE
Heart failure is a clinical syndrome caused by cardiac dysfunction usually secondary to myocardial muscle loss or dysfunction.
It is characterized by either left ventricular hypertrophy or dilation or both.
It leads to neurohormonal and circulatory abnormalities.
Acute heart failure is the rapid onset of or change in the signs and symptoms of heart failure.
It arises as a result of cardiac function deterioration in patients previously diagnosed with heart failure or may also be the first presentation of heart failure.
It is characterized by pulmonary congestion, decreased cardiac output and tissue perfusion.
It is a life-threatening condition that needs immediate medical attention.

Heart Failure - Acute Drug Information

Drug Information

Indication: Substitution treatment of essential HTN &/or stable CAD in patients already controlled w/ perindopril &...

Indication: HTN. Stable CAD: Risk reduction of cardiac events in patients w/ history of MI &/or revascularisation. 5 m...

Indication: Essential HTN in adults.

Indication: HTN. Reduce risk of stroke in patients w/ HTN & left ventricular hypertrophy (LVH). Diabetic nephropathy w...

Indication: HTN for patients in whom combination therapy is appropriate. Reduce the risk of stroke in patients w/ HTN &...

Indication: HTN for patients in whom combination therapy is appropriate. Reduce the risk of stroke in patients w/ HTN &...

Indication: Essential HTN when BP is inadequately controlled by monotherapy w/ telmisartan.

Indication: HTN, CHD (angina pectoris), stable chronic heart failure w/ reduced systolic left ventricular function in addi...

Indication: HTN. Adjunct to digitalis &/or diuretic therapy in CHF.

1  /  12
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 28 Jul 2020
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Roshini Claire Anthony, 6 days ago

Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.

Tristan Manalac, 09 Jul 2020
Left ventricular assist devices (LVADs) trigger almost immediate favourable metabolic changes in both diabetics and nondiabetics, according to a recent study.
Pearl Toh, 12 Sep 2020
Early initiation of rhythm-control therapy led to a significantly reduced risk of major adverse cardiovascular (CV) outcomes compared with usual care (typically rate control) in patients with newly diagnosed atrial fibrillation (AF) at risk of stroke, reveals the EAST-AFNET 4* trial presented at ESC 2020.